Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

2 Beaten-Down Stocks to Buy Hand Over Fist This Year


While the market bounced back last year, some stocks failed to keep pace with broader equities. That was the case with pharma giant (NYSE: ABBV) and e-commerce specialist Etsy (NASDAQ: ETSY), both of which encountered company-specific issues. Near-term headwinds aside, AbbVie and Etsy have much to offer investors, especially those willing to stay the course and hold their shares for five years or more.

Let's find out why these beaten-down stocks remain excellent buys in 2024 and beyond.

AbbVie's revenue dropped last year as it faced generic competition for its blockbuster immunology medicine Humira. Although this was a long time coming, the reality of it seems to have hit some investors hard. However, AbbVie is doing relatively fine, considering that Humira is the best-selling drug in the history of the industry, and it is now a deadweight on revenue growth.

Continue reading


Source Fool.com

AbbVie Inc. Stock

€153.08
0.590%
AbbVie Inc. gained 0.590% compared to yesterday.
The stock is an absolute favorite of our community with 21 Buy predictions and no Sell predictions.
As a result the target price of 174 € shows a slightly positive potential of 13.67% compared to the current price of 153.08 € for AbbVie Inc..
Like: 0
Share

Comments